BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Dermatol. Sep 16, 2026; 12(1): 121180
Published online Sep 16, 2026. doi: 10.5314/wjd.121180
Table 2 Survival function at years 1, 2, 3, 4 and 5 for patients receiving secukinumab and guselkumab
Drug
Measure
12 months
24 months
36 months
48 months
60 months
Secukinumab (n = 87)Patients on treatment/number of discontinuations62/543/434/525/315/1
Secukinumab (n = 87)Survival function (95%CI)82.8 (74.6-91.0)75.3 (65.5-85.0)67.9 (56.7-79.0)57.3 (44.5-70.0)49.3 (35.5-63.1)
Guselkumab (n = 62)Patients on treatment/number of discontinuations50/223/111/03/0-
Guselkumab (n = 62)Survival function (95%CI)98.2 (94.8-100)93.0 (85.2-100)87.7 (75.2-100)87.7 (79.5-95.9)-


Write to the Help Desk